Eyenovia Inc (EYEN) Tops Q2 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/11/2026
- Wall Street posts weekly gains with earnings, inflation data on tap
- Oil prices settle higher as more production shut ahead of hurricane
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
- Houthi strike on Saudi airport kills 12, worst attack on kingdom in a decade
- US consumer sentiment near record low as frustration over economy mounts
- 8.0 Mag. Earthquake 14 Km Sw Of Pitaloza Arriba Panama - USGS
- Strong Panama quake shakes nation, but avoids major destruction
- Saudi Arabia reports injuries in new attack at Riyadh airport, day after strike kills 13
Eyenovia Reports Second Quarter 2018 Financial Results
August 14, 2018 6:30 AM EDTNEW YORK, Aug. 14, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver microdosed medications topically to the eye, today announced financial results for the second quarter ended June 30, 2018.
2Q 2018 Business Highlights
EYN PG21 trial results demonstrated robust intraocular pressure lowering and patient usability;Received notice of allowance from USPTO for two additional patent applications for ophthalmic drug delivery; andExpanded executive management team by hiring industry veteran Michael Rowe... More


